Skip to content

US · CGEM · BIOTECHNOLOGY

Cullinan Therapeutics, Inc. (CGEM) intrinsic value and stock valuation

$8.89as of 2026-11-21 · Mkt cap 1.08B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cullinan Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values CGEM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CGEM’s statements →

Cullinan Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02142 cullinantherapeutics.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-219.88M
20182025
Free cash flow
-$-175.8M
20182025
Total equity
$408.7M+15.3% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$18.9M
Operating income-$-241.65M-$-196.92M-$-191.09M$144.7M-$-67.95M
Net income-$-219.88M-$-167.38M-$-153.16M$111.2M-$-65.57M
EPSd-$-3.72M-$-3.11M-$-3.69M$2.38M-$-1.48M
Operating cash flow-$-175.75M-$-145.3M-$-134.28M-$-126.66M-$-43.43M
Capital expenditure-$-50K$0.00-$-210K-$-1.13M-$-590K
Free cash flow-$-175.8M-$-145.3M-$-134.48M-$-127.8M-$-44.02M
Total assets$448.4M$621.8M$484.2M$561.1M$437.2M
Total debt$2.68M$2.15M$3.59M$5.19M$0.00
Net debt-$-85.65M-$-80.85M-$-94.84M-$-150.96M-$-59.77M
Total equity$408.7M$590.3M$453.9M$535M$425.4M
Cash and short-term investments$377.9M$399M$467.1M$467.3M$290.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$18.9M
Cost of revenue$0.00$310K$0.00$0.00$0.00
Gross profit$0.00-$-310K$0.00$0.00$18.9M
Research and development expenses$187.4M$142.9M$148.2M$92M$57.8M
Selling, general and administrative expenses$54.3M$53.7M$42.5M$40.2M$29.2M
Other expenses$0.00$0.00$440K-$-276.79M$0.00
Operating expenses$241.7M$196.6M$191.1M-$-144.65M$86.9M
Cost and expenses$241.7M$196.9M$191.1M-$-144.65M$86.9M
Interest income$22.2M$29.7M$21.6M$6.61M$480K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$310K$310K$310K$90K$50K
Ebitda-$-219.57M-$-167.15M-$-190.34M-$-132.04M-$-67.43M
Operating income-$-241.65M-$-196.92M-$-191.09M$144.7M-$-67.95M
Total other income/expenses, net$21.8M$29.5M$21.9M$6.67M$470K
Income before tax-$-219.88M-$-167.46M-$-169.22M$151.3M-$-67.48M
Income tax expense$0.00$120K-$-14.12M$42.1M$0.00
Net income-$-219.88M-$-167.38M-$-153.16M$111.2M-$-65.57M
Weighted average shares outstanding$59.1M$53.8M$41.5M$45.2M$44.3M
Weighted average diluted shares outstanding$59.1M$53.8M$41.6M$46.6M$44.3M
Balance sheet
20252024202320222021
Cash and short-term investments$377.9M$399M$467.1M$467.3M$290.5M
Net receivables$0.00$3M$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$386.8M$414.7M$480.2M$474.5M$296.6M
Property, plant and equipment, net$3.05M$2.35M$3.53M$5.3M$80K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$58.3M$204.4M$0.00$80.9M$140.4M
Total non-current assets$61.6M$207.2M$3.99M$86.6M$140.6M
Total assets$448.4M$621.8M$484.2M$561.1M$437.2M
Accounts payable$840K$1.68M$2.49M$2.66M$3.17M
Short-term debt$780K$1.3M$1.44M$1.6M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$37.7M$30.7M$28.1M$22.5M$11.8M
Long-term debt$1.9M$850K$2.15M$3.59M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.9M$850K$2.15M$3.59M$70K
Capital lease obligations$780K$2.15M$3.59M$5.01M$0.00
Total liabilities$39.6M$31.5M$30.3M$26.1M$11.8M
Common stock$10K$10K$0.00$10K$0.00
Retained earnings-$-588.12M-$-368.24M-$-200.86M-$-47.7M-$-158.91M
Accumulated other comprehensive income (loss)$1.02M-$-130K-$-130K-$-2.6M-$-840K
Total equity$408.7M$590.3M$453.9M$535M$425.4M
Total investments$347.8M$520.4M$368.6M$392M$371.1M
Total debt$2.68M$2.15M$3.59M$5.19M$0.00
Net debt-$-85.65M-$-80.85M-$-94.84M-$-150.96M-$-59.77M
Cash flow statement
20252024202320222021
Net income-$-219.88M-$-167.57M-$-153.16M$109.2M-$-67.48M
Depreciation and amortization$310K$310K$310K$90K$50K
Stock-based compensation$36M$37.8M$30.4M$28M$24.4M
Change in working capital$14.1M-$-390K-$-340K$11.2M-$-3.54M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-840K-$-810K-$-170K-$-510K-$-4.83M
Net cash provided by operating activities-$-175.75M-$-145.3M-$-134.28M-$-126.66M-$-43.43M
Investments in property, plant and equipment-$-50K$0.00-$-210K-$-1.13M-$-590K
Acquisitions, net$0.00$0.00-$-40K$275M$920K
Net cash used for investing activities$180M-$-136.31M$35.8M$249M-$-333.77M
Common stock issued$1.09M$262.7M$38.4M$8.39M$267.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.09M$266.2M$40.8M-$-25.93M$268.8M
Net change in cash$5.33M-$-15.43M-$-57.72M$96.4M-$-108.42M
Cash at end of period$88.3M$83M$98.4M$156.2M$59.8M
Operating cash flow-$-175.75M-$-145.3M-$-134.28M-$-126.66M-$-43.43M
Capital expenditure-$-50K$0.00-$-210K-$-1.13M-$-590K
Free cash flow-$-175.8M-$-145.3M-$-134.48M-$-127.8M-$-44.02M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cullinan Therapeutics, Inc.

        Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.

        CEO
        Nadim Ahmed
        Employees
        109
        Beta
        -0.01

        Explore

        Frequently asked questions

        What is the intrinsic value of Cullinan Therapeutics, Inc. (CGEM)?

        InvestorsCraft does not currently publish an intrinsic value for CGEM. How the IC value is calculated.

        Is CGEM undervalued?

        InvestorsCraft does not publish an undervaluation signal for CGEM at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.